\nInnoviva, Inc. (NASDAQ: INVA) (\u201cInnoviva\u201d or the \u201cCompany\u201d), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the second quarter ended June 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.<\/p>\n
- \n
- \nGross royalty revenue from Glaxo Group Limited (\u201cGSK\u201d) for the second quarter 2023 was $65.7 million, which included royalties of $54.4 million from global net sales of RELVAR\u00ae\/BREO\u00ae ELLIPTA\u00ae and royalties of $11.3 million from global net sales of ANORO\u00ae ELLIPTA\u00ae compared to $111.7 million for the second quarter of 2022, which included royalties of $59.3 million from global net sales of RELVAR\u00ae\/BREO\u00ae ELLIPTA\u00ae and $9.6 million from global net sales of ANORO\u00ae ELLIPTA\u00ae, respectively. The decrease was primarily due to the sale of our subsidiary, Theravance Respiratory Company, and its TRELEGY\u00ae ELLIPTA\u00ae royalty stream in July 2022.<\/p>\n<\/li>\n
- \nNet product sales and license revenue for the second quarter of 2023 was $18.7 million, which included $11.2 million from GIAPREZA\u00ae net sales, $4.5 million from XERAVA\u00ae net sales and an $3.0 million milestone payment from our partner for FDA approval of XACDURO\u00ae.<\/p>\n<\/li>\n
- \nNet income was $1.3 million, or $0.02 basic per share, for the second quarter of 2023, compared to net income of $0.9 million, or $0.01 basic per share, for the second quarter of 2022.<\/p>\n<\/li>\n
- \nCash and cash equivalents totaled $173.0 million. Royalty, product sales and milestone receivables totaled $81.0 million as of June 30, 2023.<\/p>\n<\/li>\n<\/ul>\n
\n“The second quarter of 2023 was marked by strong revenues stemming from our robust royalty portfolio and historically highest sales from our internal product portfolio,\u201d said Pavel Raifeld, Chief Executive Officer of Innoviva. \u201cWe ended the quarter on a strong note with the approval of XACDURO\u00ae (sulbactam for injection; durlobactam for injection) for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. This is the first pathogen-targeted therapy to be approved for these life-threatening infections caused by Acinetobacter Baumannii-calcoaceticus<\/i> complex, and we plan to bring this product to patients later this year. We remained disciplined on costs and saw meaningful operational progress among our investees, market volatility notwithstanding. We are excited about the prospects of our business and continue to pursue shareholder value accretive activities, such as share repurchases.\u201d<\/p>\n
Second Quarter 2023 and Recent Highlights<\/b><\/p>\n
GSK Net Sales<\/i><\/p>\n
- \n
- \nSecond quarter 2023 net sales of RELVAR\u00ae\/BREO\u00ae ELLIPTA\u00ae by GSK were $363.0 million with $149.8 million in net sales from the U.S. market and $213.2 million from non-U.S. markets.<\/p>\n<\/li>\n
- \nSecond quarter 2023 net sales of ANORO\u00ae ELLIPTA\u00ae by GSK were $173.3 million with $85.5 million net sales from the U.S. market and $87.8 million from non-U.S. markets.<\/p>\n<\/li>\n<\/ul>\n
Corporate Updates<\/i><\/p>\n
- \n
- \nDuring the second quarter of 2023, Innoviva repurchased 775,504 shares of its outstanding common stock for $9.2 million.<\/p>\n<\/li>\n
- \nOn July 11, 2023, Innoviva\u2019s wholly owned subsidiary, Innoviva Strategic Opportunities, entered into a credit and security agreement with Armata Pharmaceuticals, Inc. (NYSE: ARMP) (\u201cArmata\u201d) and invested $25.0 million to advance Armata\u2019s pipeline of therapeutic phage candidates and support the build-out of its state-of-the art cGMP manufacturing facility.<\/p>\n<\/li>\n
- \nOn July 11, 2023, Innoviva director, Deborah Birx, resigned from Innoviva Board and joined Armata as Chief Executive Officer.<\/p>\n<\/li>\n<\/ul>\n
Clinical Updates<\/i><\/p>\n
- \n
- \nOn May 23, 2023, Innoviva\u2019s wholly owned subsidiary, Innoviva Specialty Therapeutics, received FDA\u2019s approval of XACDURO\u00ae (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP\/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus<\/i> complex (Acinetobacter<\/i>). The company is preparing to launch XACDURO\u00ae later this year.<\/p>\n<\/li>\n
- \nRecruitment is now complete in the registrational Phase 3 Zoliflodacin study. Oral Zoliflodacin is a novel oral antibiotic in development for the treatment of uncomplicated gonorrhea infection. Top-line results for this ongoing Phase 3 trial are expected in late 2023.<\/p>\n<\/li>\n<\/ul>\n
About Innoviva<\/b><\/p>\n
\nInnoviva is a diversified holding company with a portfolio of royalties and other healthcare assets. Innoviva\u2019s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (\u201cGSK\u201d), including RELVAR\u00ae<\/sup>\/BREO\u00ae<\/sup> ELLIPTA\u00ae<\/sup> (fluticasone furoate\/ vilanterol, \u201cFF\/VI\u201d) and ANORO\u00ae<\/sup> ELLIPTA\u00ae<\/sup> (umeclidinium bromide\/ vilanterol, \u201cUMEC\/VI\u201d). Under the Long-Acting Beta2 Agonist (\u201cLABA\u201d) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR\u00ae<\/sup>\/BREO\u00ae<\/sup> ELLIPTA\u00ae<\/sup> and ANORO\u00ae<\/sup> ELLIPTA\u00ae<\/sup>. Innoviva\u2019s other innovative healthcare assets include infectious disease and hospital assets stemming from acquisitions of Entasis Therapeutics, including XACDURO\u00ae (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus<\/i> complex (Acinetobacter<\/i>) and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA\u00ae (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA\u00ae (eravacycline) for the treatment of complicated intra-abdominal infections in adults.<\/p>\n
\nANORO\u00ae<\/sup>, RELVAR\u00ae<\/sup> and BREO\u00ae<\/sup> are trademarks of the GSK group of companies.<\/p>\n
Forward Looking Statements<\/b><\/p>\n
\nThis press release contains certain \u201cforward-looking\u201d statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words \u201canticipate\u201d, \u201cexpect\u201d, \u201cgoal\u201d, \u201cintend\u201d, \u201cobjective\u201d, \u201copportunity\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201ctarget\u201d and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR\u00ae<\/sup>\/BREO\u00ae<\/sup> ELLIPTA\u00ae<\/sup>, ANORO\u00ae<\/sup> ELLIPTA\u00ae<\/sup>, GIAPREZA\u00ae<\/sup>, XERAVA\u00ae<\/sup> and XACDURO\u00ae<\/sup> in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva\u2019s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (\u201cCOVID-19\u201d); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company\u2019s growth strategy. Other risks affecting Innoviva are described under the headings \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d contained in Innoviva\u2019s Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (\u201cSEC\u201d) and available on the SEC\u2019s website at www.sec.gov<\/a>. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.<\/p>\n
\n
\n INNOVIVA, INC.<\/td>\n<\/tr>\n \n Condensed Consolidated Statements of Income<\/td>\n<\/tr>\n \n (in thousands, except per share data)<\/td>\n<\/tr>\n \n (Unaudited)<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n Three Months Ended<\/td>\n \n Six Months Ended<\/td>\n<\/tr>\n \n June 30,<\/td>\n \n June 30,<\/td>\n<\/tr>\n \n \n \n \n2023<\/p>\n<\/td>\n
\n \n \n2022<\/p>\n<\/td>\n
\n \n \n2023<\/p>\n<\/td>\n
\n \n \n2022<\/p>\n<\/td>\n<\/tr>\n
\n Revenue:<\/td>\n \n \n \n \n \n \n <\/tr>\n \n Royalty revenue, net (1)<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n62,265<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n108,220<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n119,123<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n198,279<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net product sales<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n15,727<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n27,241<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n License revenue<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,000<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n11,000<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Total revenue<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n80,992<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n108,220<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n157,364<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n198,279<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Expenses:<\/td>\n \n \n \n \n \n \n <\/tr>\n \n Cost of products sold (inclusive of amortization of inventory fair value
adjustments, excluding depreciation and amortization of intangible assets)<\/td>\n\n \n\u00a0<\/p>\n<\/td>\n
\n \n8,979<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n17,728<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Cost of license revenue<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,600<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Selling, general and administrative<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n23,542<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n11,782<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n43,277<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n18,274<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Research and development<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n14,989<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n13,884<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n27,577<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n19,722<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Amortization of acquired intangible assets<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n4,958<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n8,763<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Loss on debt extinguishment<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,662<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Changes in fair values of equity method investments, net<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n19,911<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n42,823<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n4,094<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n54,773<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Changes in fair values of equity and long-term investments, net<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n83<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n15,777<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n2,247<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n13,238<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Interest and dividend income<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(3,553<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(724<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(6,918<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(1,046<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Interest expense<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n4,382<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,655<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n8,809<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n6,665<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Other expense, net<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,896<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n528<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,242<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n778<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Total expenses<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n75,187<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n87,725<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n110,419<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n133,066<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Income before income taxes<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n5,805<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,495<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n46,945<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n65,213<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Income tax expense<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n4,525<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(876<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n10,800<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n5,984<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net income<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,280<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n21,371<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n36,145<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n59,229<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net income attributable to noncontrolling interest<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,432<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n42,517<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net income attributable to Innoviva stockholders<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n1,280<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n939<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n36,145<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n16,712<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Basic net income per share attributable to Innoviva stockholders<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n0.02<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n0.01<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n0.54<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n0.24<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Diluted net income per share attributable to Innoviva stockholders<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n0.02<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n0.05<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n0.46<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n0.24<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Shares used to compute basic net income per share<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n65,341<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n69,643<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n66,557<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n69,594<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Shares used to compute diluted net income per share<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n65,489<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n95,653<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n88,175<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n94,692<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n
\n (1) Total net revenue is comprised of the following (in thousands):<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n Three Months Ended<\/td>\n \n Six Months Ended<\/td>\n<\/tr>\n \n June 30,<\/td>\n June 30,<\/td>\n<\/tr>\n \n \n \n \n2023<\/p>\n<\/td>\n
\n \n \n2022<\/p>\n<\/td>\n
\n \n \n2023<\/p>\n<\/td>\n
\n \n \n2022<\/p>\n<\/td>\n<\/tr>\n
\n \n (unaudited)<\/td>\n \n (unaudited)<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Royalties<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n65,721<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n111,676<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n126,035<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n205,191<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Amortization of capitalized fees<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(3,456<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(3,456<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(6,912<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(6,912<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Royalty revenue, net<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n62,265<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n108,220<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n119,123<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n198,279<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n
\n \u00a0<\/td>\n<\/tr>\n \n INNOVIVA, INC.<\/td>\n<\/tr>\n \n Condensed Consolidated Balance Sheets<\/td>\n<\/tr>\n \n (in thousands)<\/td>\n<\/tr>\n \n (unaudited)<\/td>\n<\/tr>\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n June 30,<\/td>\n \n December 31,<\/td>\n<\/tr>\n \n \n \n \n2023<\/p>\n<\/td>\n
\n \n \n2022<\/p>\n<\/td>\n<\/tr>\n
\n Assets<\/td>\n \n \n <\/tr>\n \n Cash and cash equivalents<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n173,025<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n291,049<\/p>\n<\/td>\n<\/tr>\n
\n Royalty and product sale receivables<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n80,996<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n64,073<\/p>\n<\/td>\n<\/tr>\n
\n Inventory, net<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n46,846<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n55,897<\/p>\n<\/td>\n<\/tr>\n
\n Prepaid expense and other current assets<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n22,671<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n32,492<\/p>\n<\/td>\n<\/tr>\n
\n Property and equipment, net<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n161<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n170<\/p>\n<\/td>\n<\/tr>\n
\n Equity and long-term investments<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n433,001<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n403,013<\/p>\n<\/td>\n<\/tr>\n
\n Capitalized fees<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n90,695<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n97,607<\/p>\n<\/td>\n<\/tr>\n
\n Right-of-use assets<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n2,719<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,265<\/p>\n<\/td>\n<\/tr>\n
\n Goodwill<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n14,882<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n26,713<\/p>\n<\/td>\n<\/tr>\n
\n Intangible assets<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n243,356<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n252,919<\/p>\n<\/td>\n<\/tr>\n
\n Deferred tax assets<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n6,327<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n<\/tr>\n
\n Other assets<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,562<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n4,299<\/p>\n<\/td>\n<\/tr>\n
\n Total assets<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n1,118,241<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n1,231,497<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Liabilities and stockholders\u2019 equity<\/td>\n \n \n <\/tr>\n \n Other current liabilities<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n32,722<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n32,322<\/p>\n<\/td>\n<\/tr>\n
\n Accrued interest payable<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,422<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n4,359<\/p>\n<\/td>\n<\/tr>\n
\n Deferred revenue<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,254<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n2,094<\/p>\n<\/td>\n<\/tr>\n
\n Convertible subordinated notes, due 2023, net<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n96,193<\/p>\n<\/td>\n<\/tr>\n
\n Convertible senior notes, due 2025, net<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n190,937<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n190,583<\/p>\n<\/td>\n<\/tr>\n
\n Convertible senior notes, due 2028, net<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n254,264<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n253,597<\/p>\n<\/td>\n<\/tr>\n
\n Other long term liabilities<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n68,584<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n70,918<\/p>\n<\/td>\n<\/tr>\n
\n Deferred tax liabilities<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n5,771<\/p>\n<\/td>\n<\/tr>\n
\n Income tax payable – long term<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n9,971<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n9,872<\/p>\n<\/td>\n<\/tr>\n
\n Innoviva stockholders\u2019 equity<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n555,087<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n565,788<\/p>\n<\/td>\n<\/tr>\n
\n Total liabilities and stockholders\u2019 equity<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n1,118,241<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n1,231,497<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n
\n INNOVIVA, INC.<\/td>\n<\/tr>\n \n Cash Flows Summary<\/td>\n<\/tr>\n \n (in thousands)<\/td>\n<\/tr>\n \n (unaudited)<\/td>\n<\/tr>\n \n \n \u00a0<\/td>\n<\/tr>\n \n \n Six Months Ended June 30,<\/td>\n<\/tr>\n \n \n \n \n2023<\/p>\n<\/td>\n
\n \n \n2022<\/p>\n<\/td>\n<\/tr>\n
\n Net cash provided by operating activities<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n63,866<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n177,137<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net cash used in investing activities<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(35,722<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(145,678<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Net cash (used in) provided by financing activities<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(146,168<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n50,596<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net change<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n(118,024<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n82,055<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Cash and cash equivalents at beginning of period<\/td>\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n291,049<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n201,525<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Cash, cash equivalents and restricted cash at end of period<\/td>\n \n \n$<\/p>\n<\/td>\n
\n \n173,025<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n283,580<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n\u00a0<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230802433840\/en\/<\/a><\/span><\/p>\n
Investors and Media Contact:
\n<\/b>
Argot Partners
\n
(212) 600-1902
\n
innoviva@argotpartners.com<\/a><\/p>\nKEYWORDS:<\/b> California United States North America<\/p>\n
INDUSTRY KEYWORDS:<\/b> Research Infectious Diseases FDA Clinical Trials Biotechnology Health Pharmaceutical Other Science Science<\/p>\n
- \nRecruitment is now complete in the registrational Phase 3 Zoliflodacin study. Oral Zoliflodacin is a novel oral antibiotic in development for the treatment of uncomplicated gonorrhea infection. Top-line results for this ongoing Phase 3 trial are expected in late 2023.<\/p>\n<\/li>\n<\/ul>\n
- \nOn May 23, 2023, Innoviva\u2019s wholly owned subsidiary, Innoviva Specialty Therapeutics, received FDA\u2019s approval of XACDURO\u00ae (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP\/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus<\/i> complex (Acinetobacter<\/i>). The company is preparing to launch XACDURO\u00ae later this year.<\/p>\n<\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230802433840\/en\/1857484\/3\/innoviva_navy_resized_copy_%281%29.jpg\")
<\/td>\n<\/tr>\n